研究文章雷竞技app下载苹果版

代谢状态的患者Hypoestrogenic停止排卵长期激素替代疗法

文摘

27 hypoestrogenic患者停止排卵(11 - hypogonadotropic性腺机能减退(HH)和16 -卵巢功能早衰(POF)观察了超过5(6.9±1.8)年。这项研究的平均年龄在HH患者为28.5±4.9岁,与POF - 36.3±6.4年。雌二醇/ dydrogesterone (E2 / D)是用于11例(n = 4 - HH;n = 7 - POF)雌二醇戊酸酯/ levonorgestrel (EV / LNG) - 16例(n = 7 - HH;n = 9 - POF)。胰岛素抵抗的患病率显著增加26(92.3%)和20例(74.1%)χ2 A / D p < 0.01)。进行逐步回归方法找到恶化的最重要的预测患者的胰岛素敏感性hypoestrogenism长期激素替代疗法(HRT)。分析彼此的累积效应等因素:药物的选择激素替代治疗,年龄、BMI在研究结束时,甘油三酸酯水平,家庭的既往症2型糖尿病(T2D),已确定增加的主要预测指数HOMA只有家庭记忆T2D (R = 0.92;p = 0.00)。高甘油三酯血症的频率也大大增加(9(33.3%)和6(22.2%)χ2 A / D p < 0.05)。 The main predictor of growth hypertriglyceridemia recognized age of women at the end of the study (R=0.49; p<0.05), but the choice of the medicine. The number of women with impaired glucose tolerance increased to 14.8% (vs. 0%) χ2 A/D 21.0; p<0.001). Predictors of IGT (T2D) patients with hypoestrogenism on the long-term HRT called HOMA index (R=0.74; p<0.01) and anamnesis for T2D (R=0.76; p<0.001). HRT does not protect the deterioration of insulin sensitivity in patients with a family anamnesis of T2D and is not a means of prevention of this disease.

Chagay NB

阅读全文下载全文|访问全文